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Abstract Genetic background plays an important role in the
development of Dupuytren’s disease. A genome-wide associ-
ation study (GWAS) showed that nine loci are associated with
the disease, six of which contain genes that are involved in
Wnt signaling (WNT2, WNT4, WNT7B, RSPO2, SFRP4,
SULF1). To obtain insight in the role of these genes, we per-
formed expression studies on affected and unaffected patient’s
tissues. Surgically obtained nodules and cords from eight
Dupuytren’s patients were compared to patient-matched con-
trol tissue (unaffected transverse palmar fascia). The Wnt-
related genes found in the GWAS, the classical Wnt-
downstream protein β-catenin, as well as (myo)fibroblast
markers were analyzed using real-time qPCR and immunohis-
tochemical stainings for mRNA levels and protein levels, re-
spectively. The collagen-coding genes COL1A1 and COL3A1
were highly upregulated on mRNA level, both in cords and
nodules. ThreeWnt-related genes were found to be differently
regulated compared to control tissue: WNT2 was downregu-
lated in nodules, WNT7B was upregulated in nodules, and
SFRP4 was upregu la t ed in nodu les and cords .
Immunohistochemistry revealed significantly less staining of
Wnt2 in cords, but significantly more staining for Wnt7b in
nodules. There was significantly more staining of α-SMA in
nodules and cord and β-catenin in nodules than in control
tissue. We found differences in expression, both at mRNA
and protein level, in several Wnt-related genes found earlier
to be associated with Dupuytren’s disease. Of these, Wnt7b
was upregulated and found in close association with both α-
SMA and β-catenin expressing cells, making it a candidate
pro-fibrotic mediator in Dupuytren’s disease.
Keywords β-catenin . Dupuytren’s disease . Fibrosis .Wnt
signaling
Abbreviations
GWAS Genome-wide association study
TLPA Transverse ligaments of the palmar aponeurosis
PBS Phosphate buffered saline
q
(RT)PCR
Quantitative (real-time) polymerase chain
reaction
Introduction
Dupuytren’s disease is a benign fibroproliferative disorder of
the hand, which causes the formation of nodules and cords in
the palm and fingers. It may eventually lead to the inability to
fully extend the fingers. The prevalence varies from 1 % to
32% inWestern countries (Lanting et al. 2013). The disease is
more common in people of European ancestry, in older per-
sons and in males (Gudmundsson et al. 2000; Hindocha et al.
2009). The main treatment option has until recently been open
surgery, but use of less invasive methods, such as percutane-
ous needle fasciotomy and collagenase injections in the cords,
is becoming more popular (van Rijssen et al. 2012; Hurst et al.
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2009). However, there is no definitive cure and recurrences
are frequent (van Rijssen et al. 2012).
Pathophysiologically, both contraction and matrix deposi-
tion caused by uncontrolled myofibroblast activity in and
around the palmar fascia of the hand are key features
(Tomasek et al. 1987). The development of myofibroblasts
in general depends on a number of different environmental
cues, including tension in the matrix and exposure to a variety
of different mediators, such as transforming growth factor-β1
(Hinz 2007). Myofibroblasts have been suggested to make up
the majority of nodular cells, with cords being less cellular and
more tendon-like (Verjee et al. 2009).
Several causes have been proposed for Dupuytren’s dis-
ease, and a genetic component is one of them. Concerning this
genetic predisposition, in a genome-wide association study
(GWAS), nine chromosomal loci were found to be associated
with susceptibility to Dupuytren’s disease (Dolmans et al.
2011). Six of these loci contain genes involved in the Wnt
signaling pathway. The canonical pathway of Wnt signaling
is the most extensively studied and has been shown to pro-
mote cell proliferation and survival via β-catenin (Moon et al.
2004; Rao and Kuhl 2010). Alternatively, Wnt proteins may
signal via the non-canonical Wnt pathway, defined as all Wnt
signaling activities that operate independently of β-catenin.
The Wnt-related genes that have been identified in the
GWAS are WNT2, WNT4, WNT7B, RSPO2, SFRP4 and
SULF1 (Fig. 1). Of these, three Wnt proteins exert their effect
through binding to Frizzled receptors, causing a nuclear trans-
location of β-catenin via the canonical pathway. They may
also activate the non-canonical pathway via Frizzled and other
receptors. Secreted Frizzled-related proteins (Sfrp) bind to
Wnt proteins, thereby inhibiting normal Wnt-Frizzled interac-
tions. R-Spondin activates the pathway by interacting with
Frizzled receptors, Lrp5/6 and Dkk proteins (Rao and Kuhl
2010). Sulf1 is a member of the sulfatase gene family that also
interacts with canonical Wnt signaling, although the mecha-
nism is unclear: both activation and inhibition of Wnt signal-
ing have been described (Sahota and Dhoot 2009).
Although the association between the Wnt pathway
and Dupuytren’s disease, as described by Dolmans
et al., has been confirmed in three independent associa-
tion studies (Dolmans et al. 2011; Shih et al. 2012;
Anderson et al. 2014). the expression/involvement of
Wnt pathway members in diseased Dupuytren’s tissue
is unclear. An increased protein expression and nuclear
translocation of β-catenin has repeatedly been reported
(Varallo et al. 2003; Howard et al. 2003; Montgomery
and Folpe 2005; O’Gorman et al. 2006; Degreef et al.
2009; Vi et al. 2009), but reports on mRNA expression
and protein localization data on the Wnt pathway are
rare and seem to be contradictory (O’Gorman et al.
2006; Degreef et al. 2009). In this study we have in-
vestigated the expression and protein localization of the
six genes identified in the GWAS in affected nodules
and cords of eight Dupuytren’s patients, and used unaf-
fected fascia of the same donors as control tissue. By
doing so, we were able to investigate the presence of
mRNA levels of several Wnt-related genes and their
corresponding proteins in affected and non-affected tis-
sues. Collagen type I and III and alfa-smooth muscle
actin (α-SMA) were measured to obtain an impression
of the diseased state of the cords and nodules.
Fig. 1 The tested Wnt-related
genes and proteins and their
functions in the canonical Wnt
signaling pathway are shown
here. On the left, theWnt pathway
is inhibited: β-catenin (β-cat) is
degraded in the abcense of a Wnt
protein. On the right, the Wnt
pathway is activated: a
translocation of β-catenin to the
nucleus when aWnt protein binds
to the Frizzled receptorr
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Material and methods
Primary tissues
Dupuytren’s nodules, cords and unaffected transverse liga-
ments of the palmar aponeurosis (TLPA) were obtained from
Dupuytren’s patients with primary disease that underwent lim-
ited fasciectomy or dermofasciectomy by plastic surgeons in
the University Medical Center Groningen. Nodules and cords
were considered affected, and TLPAwas considered unaffect-
ed (control). All affected and control tissues were patient-
matched.
Quantitative RT-PCR
Up to 30 mg of tissue per sample was cut into small
pieces and disrupted using an ultra-turrax. RNA extrac-
tion was performed using the RNeasy Fibrous Tissue
Mini Kit (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions. RNA was quantified using a
NanoDrop-1000 spec t rophotometer (NanoDrop
Technologies, Wilmington, DE). Complementary DNA
was synthesized from RNA using the RevertAid First
Strand cDNA Synthesis Kit (Thermo Scientific,
Rockford, IL). Primers were ordered from Sigma-
Aldrich (Zwijndrecht, The Netherlands) (sequences:
Table 1). Samples were analyzed in triplo (Wnt-
related) or duplo (others) and pipetted onto MicroAmp
Optical 384-Well Reaction Plates with Barcode (Applied
Biosystems, Foster City, CA). Plates were run on the
ViiA 7 Real-Time PCR system (Applied Biosystems).
The relative amount of product was calculated using
the ΔΔCt method, normalizing for the averaged expres-
sion of the household genes GAPDH and YWHAZ and
related to the control tissue.
Immunohistochemistry
Frozen tissue on Tissue-Tek (Sakura, Zoeterwoude,
The Netherlands) was cut into 5–10 μm coupes and
put onto microscope slides (Starfrost, Waldemar Knittel
GmbH, Brunschweig, Germany). Sections were fixed for
10 min with acetone (stainings for Wnt2, Wnt7b, Sfrp4,
α-SMA), or 4 % paraformaldehyde in PBS with perme-
abilization using 0.1 % Triton X (stainings for Wnt4,
Rspo2, Sulf1, β-catenin, Collagen-I, Collagen-III). The
sections were incubated with a primary antibody for
60 min at room temperature, with 1 % bovine serum
albumin (an t ibody informat ion : see Table 2) .
Endogenous peroxidases were blocked using 0.1 %
H2O2 during 15 min. For all biotinylated secondary an-
tibodies, avidin and biotin were blocked for 15 min
using the Biotin Blocking System (Dako, Glosstrup,
Denmark). Secondary antibodies (Dako and Southern
Biotech, Birmingham, AL) diluted 1:100 with 2 % hu-
man serum, were incubated during 30 min. The
s t a i n i n g s we r e v i s u a l i z e d u s i ng 3 - am ino - 9 -
ethylcarbazole (AEC; Sigma-Aldrich) or Vector Red
(Vector Laboratories, Burlingame, CA). Hematoxylin
(Me r c k , D a rms t a d t , G e rmany ) wa s u s e d a s
counterstaining and all slides were mounted in Kaiser’s
glycerin-gelatin (Merck).
Quantification of stainings
Stainings were analyzed using a Leica DM 2000 micro-
scope (Leica, Wetzlar, Germany). For quantification,
three to five representative photomicrographs (40× mag-
nification) were taken per tissue section, and analyzed
using Nuance 3.0 software (PerkinElmer, Waltham,
MA), allowing detection of a specific signal without
interfering background noise. For each specific staining,
stained areas were quantified as μm2/high power field.
Statistics
Statistical analysis was performed using GraphPad Prism
version 5 (GraphPad Software, La Jolla, CA). A
Kruskal-Wallis test was used to determine whether there
were differences in ranks between the three groups. A
post-hoc Dunn’s Multiple Comparisons test compared
controls with cords and controls with nodules. P values
<0.05 were considered to be statistically significant.
Graphs show individual sample values, accompanied
by a mean with SEM whisker plot per group.
Signif icances are shown as * (P < 0.05) ; **
(P < 0.01) and *** (P < 0.001).
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Results
Characterization of tissue: collagen and α-smooth muscle
actin
Tissues were characterized by real-time qPCR and im-
munohistochemical stainings on nodules, cords and con-
trol tissue in terms of expression of ACTA2/α-SMA,
COL1A1/collagen type I and COL3A1/collagen type
III. We did not find significant differences in mRNA
expression of ACTA2 between affected tissues and con-
trol, but observed a high upregulation of both COL1A1
and COL3A1 in both cords and nodules (Supplemental
Fig. 1a). At protein level we found significantly more
α-SMA, the main marker for myofibroblasts, in cord
and nodules than in control tissue (Supplemental
Fig. 1b). These stainings clearly showed a pattern of
different zones of high intensity within the affected tis-
sues. Both collagens were highly upregulated in cords at
protein level, while collagen type III only showed a
significant upregulation in nodules (Supplemental
Fig. 1c-e).
MRNA expression of Wnt-related genes
The six Wnt-related genes that were found to be asso-
ciated with Dupuytren’s disease in the GWAS (Dolmans
et al. 2011) were analyzed in eight (SULF1: seven)
affected cords and nodules and in unaffected TLPA by
performing real-time qPCR. Significant expression dif-
ferences in three of these genes were found in affected
tissue compared to control tissue: a nine-fold downreg-
ulation of WNT2 in nodules (P < 0.01), a five-fold
upregulation of WNT7B in nodules (P < 0.01), and a
two-fold upregulation of SFRP4 in cords as well as
nodules (p < 0.01). (Fig. 2) We did not find any
significant differences in expression of WNT4, RSPO2
and SULF1.
Immunohistochemistry
Significantly less staining of theWnt2 protein was observed in
cords than in controls (P < 0.05). Also, we found moreWnt7b
staining (P < 0.05) in nodules than in controls (Fig. 3). Both
results are in agreement with the qPCR results (Fig. 2). There
were no significant differences in staining for Wnt4, Rspo2,
Sfrp4 and Sulf1 (data not shown). β-catenin, which is the
common downstream target of the canonical Wnt pathway,
showed significantly more staining in nodules than in controls
(P < 0.05) (Fig. 4a,b). A larger percentage of this staining was
associated with the nucleus compared to controls (Fig. 4c).
Finally, using staining of serial sections, we found that
stainings for Wnt7b and β-catenin clustered in or around the
zones with a positive α-SMA staining (Fig. 4d).
Discussion
We examined the expression of the Wnt-related genes found
to be associated with Dupuytren’s disease in the GWAS by
Dolmans et al. (2011). as well as the corresponding proteins
and the Wnt downstream target β-catenin. We found that sev-
eralWnt-related genes were differentially regulated in affected
tissue compared to control tissue. Specifically, we report
upregulation of WNT7B and SFRP4 and downregulation of
WNT2. We also found a clear increase in expression of Wnt-
downstream protein β-catenin in Dupuytren’s nodules, espe-
cially in nuclei, strongly suggesting an overall activation of
the canonical Wnt signaling pathway in Dupuytren’s disease.
Dolmans et al. (2011) found single nucleotide polymor-
phisms in six areas where several Wnt genes are coded to be
associated with Dupuytren’s. They concluded that these genes
could be relevant in the occurrence and development of the
Table 2 Primary antibodies used for immunohistochemical stainings
Antibody Manufacturer Product Code Dilution
Wnt2 R&D, Minneapolis, MN AF3464 1:50
Wnt4 Sigma-Aldrich, Zwijndrecht, The Netherlands HPA011397 1:50
Wnt7b Sigma-Aldrich, Zwijndrecht, The Netherlands SAB2104506 1:200
R-Spondin2 Santa Cruz Biotechnology, Santa Cruz, CA SC-74,883 1:100
Sfrp4 Sigma-Aldrich, Zwijndrecht, The Netherlands HPA009712 1:25
Sulf1 Santa Cruz Biotechnology, Santa Cruz, CA SC-98,325 1:100
β-catenin BD Transduction Laboratories, San Diego, CA 610,153 1:100
α-SMA Dako, Glosstrup, Denmark M0851 1:100
Collagen-I Abcam, Cambridge, MA 6308 1:5000
Collagen-III Abcam, Cambridge, MA 6310 1:5000
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disease. In accordance with this, we show three of these genes
to be differentially expressed between normal and affected
tissues within patients, extending the findings of the GWAS
study. Not all Wnt-related genes found in the GWAS showed
an altered regulation in our study. Our limited study size, as
well as the different study design, since we used internal
Fig. 2 mRNA levels of WNT-
related genes in Dupuytren’s
disease tissue (cord, nodule) as
compared to control tissue
(unaffected transverse ligaments
of the palmar aponeurosis). Upper
panel: WNT2, WNT4, WNT7B;
lower panel: RSPO2, SFRP4 and
SULF1. * P < 0.05, ** P < 0.01
by Kruskal-Wallis test, followed
by post-hoc Dunn’s Multiple
Comparisons test
Fig. 3 Representative pictures
and quantification of staining of
selected Wnt-proteins in
Dupuytren’s disease tissue (cords,
nodule) as compared to control
tissue (unaffected transverse
ligaments of the palmar
aponeurosis). aWnt2. bWnt7b. *
P < 0.05 by Kruskal-Wallis test,
followed by post-hoc Dunn’s
Multiple Comparisons test
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instead of external controls, might be responsible for this. A
previous study showed that differences between affected fi-
broblasts and fibroblasts from unaffected fascia in
Dupuytren’s patients are smaller than those between palmar
fascia fibroblasts from healthy persons and affected fibroblasts
from Dupuytren’s patients (Satish et al. 2012). In line with
these findings, we did indeed find less differences, however,
these can all be ascribed to the disease process, since inter-
patient variation does not play a role in our study set-up.
Besides, TLPA may seem unaffected during surgery, but con-
tain microscopical spurs of disease that influence the outcome
of PCR and immunohistochemical examinations. Expression
profiles of ACTA2/α-SMA, COL1A1/collagen type I and
COL3A1/collagen type III onmRNA and/or protein level con-
firmed that the affected tissues were fibrotic, as compared to
the control TLPA. These data contribute to the validation of
our findings regarding Wnt signaling and β-catenin in
Dupuytren’s tissues.
Of the 19Wnt-ligand genes in the human genome (Clevers
and Nusse 2012) we studied three: WNT2, WNT4 and
WNT7B. Next to these Wnt ligands, we examined three genes
that influence Wnt signaling: SFRP4, RSPO2 and SULF1.
The Wnt-related genes that we analyzed have different func-
tions in the Wnt signaling pathway. We found theWNT2 gene
to be lower expressed in Dupuyten’s nodules, and the Wnt2
protein to have less staining in cords compared to controls. In
view of the general profibrotic role ascribed to the Wnt path-
way this is a remarkable finding. Wnt2 has been specifically
linked to fibrosis before, for instance by Bayle et al., who
found an increased mRNA expression of WNT2 in a mouse
model of skin fibrosis (Bayle et al. 2008). Possibly, a negative
feedback mechanism in which the WNT2 gene is being sup-
pressed as a reaction to excessive activation of the Wnt sig-
naling pathway, plays a role in Dupuytren’s disease. In this
context, it is of interest to note thatWNT2was also found to be
a susceptibility locus in the related Peyronie’s disease, in
which the penis is affected (Dolmans et al. 2012). However,
it is not known whether in this diseaseWNT2 is up- or down-
regulated. Further study is needed to prove a similar downreg-
ulation in Peyronie’s disease.
In contrast to the lower expression of the WNT2 gene and
protein in Dupuytren’s tissue, we found a significantly higher
expression of theWNT7B gene in nodules compared to control
tissue, and moreWnt7b positive cells in nodules. This gene has
Fig. 4 Representative pictures and quantification of staining ofβ-catenin
in Dupuytren’s disease tissue (cord, nodule) as compared to control tissue
(unaffected transverse ligaments of the palmar aponeurosis). a
photomicrographs. b quantification of staining for β-catenin. * P < 0.05
by Kruskal-Wallis test, followed by post-hoc Dunn’s Multiple
Comparisons test. c percentage of nuclear localization measured as
colocalization of β-catenin positive signal with hematoxylin signal. *
P < 0.05 by Kruskal-Wallis test, followed by post-hoc Dunn’s Multiple
Comparisons test. d) Staining for Wnt7b, β-catenin and α-smooth
muscle actin (scale bar represents 100 μm) in serial sections of a
Dupuytren’s nodule
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been reported to play a role in several pulmonary conditions. A
higher expression of WNT7B was found in lung tissue from
patients with idiopathic pulmonary fibrosis, on mRNA
(Konigshoff et al. 2008) and protein level. The increased im-
munostaining of the Wnt7b protein was found especially in
regions with fibrotic changes (Meuten et al. 2012). which is
in accordance with our findings in nodule, where Wnt7b stain-
ing was found in α-SMA positive areas. Overall, these and our
findings seem to pinpoint WNT7B as an important effector
molecule in fibrosis. If so, a higher expression of WNT7B in
affected tissue of Dupuytren’s patients seems a likely candidate
to be connected with the disease process, either as a cause or
consequence.
We found a significantly (two-fold) higher expression of
the SFRP4 gene in cords and nodules, but no differences in
protein staining. SFRP4 codes for one of the secreted Frizzled-
related proteins, a group of Wnt-binding proteins that inhibit
interactions between Wnt and Wnt receptors (Clevers and
Nusse 2012). but it has also been reported to activate Wnt
signaling (Mahdi et al. 2012). Shih et al. found a higher
mRNA expression of SFRP4 in Dupuytren’s tissues (Shih
et al. 2012). In humans with systemic sclerosis, an upregula-
tion of SFRP4 on mRNA and protein level was found in
fibrotic skin (Bayle et al. 2008). On the other hand, Sfrp4
administration in rats reduces fibrosis after ischemic injury
to the heart, and a therapeutical effect of recombinant Sfrp4
on renal fibrosis in mice has been described (Matsushima et al.
2010; Surendran et al. 2005). Our findings showed a higher
transcriptional expression of SFRP4, but – in the absence of a
change in protein levels – the effect of this remains unclear.
Several studies have reported increased β-catenin in
Dupuytren’s disease and discussed a dysregulation of the Wnt
signaling pathway as an upstream regulator of β-catenin
(Varallo et al. 2003; Montgomery and Folpe 2005; O’Gorman
et al. 2006; Degreef et al. 2009). Varallo et al. described higher
levels of β-catenin in diseased palmar fascia as compared to
patient-matched normal fascia, with both cytoplasmic and nu-
clear staining. They suggested thatWnt signaling might contrib-
ute to these findings, but a role of TGF-β and the extracellular
matrix was also suggested (Varallo et al. 2003). O’Gorman et al.
found that changes in Wnt expression are unlikely to be the
cause of dysregulation of β-catenin expression in Dupuytren’s
disease. They reported that overall Wnt expression, with the
exception of WNT10B, was unchanged between normal and
disease palmar fascia on mRNA level, but they did not examine
protein expression (O’Gorman et al. 2006). Degreef et al. found
evident staining of β-catenin in involutional zones of
Dupuytren’s nodules, without comparing it to control tissue.
They found no differences between nodules of patients with
recurrent and non-recurrent disease (Degreef et al. 2009). We
found significantlymore staining ofβ-catenin in nodules than in
control tissue, and the relative amount of staining associated
with nuclei was much higher than in controls, confirming
activation of the Wnt signaling cascade. In view of the high
expression of Wnt7b in the same region as nuclear β-catenin,
this protein might be among the Wnt proteins causing the acti-
vation of the Wnt pathway in this tissue.
Based on our results, the Wnt signaling pathway is
(over)activated in Dupuytren’s disease, which would make
inhibition of this pathway an interesting possible treatment
target. Although systemic therapy influencing the Wnt path-
way might not be a realistic solution, in view of its ubiquitous
importance in cellular processes, local injections with Wnt-
blocking agents as a preventive measure may be a possibility.
However, our study does not address the question whether the
activated Wnt pathway is the cause or the result of
Dupuytren’s disease. In either case, inhibition of theWnt path-
way will have to be tested further in vitro and in vivo, before it
would make a feasible treatment.
Conclusion
In this study we report dysregulation of several Wnt-related
genes and proteins, although not all genes found in the GWAS
were changed. We found an increase in Wnt-target β-catenin
in affected tissue, indicating activation of the canonical Wnt-
signaling pathway. In addition, we found a substantial upreg-
ulation of Wnt7b, which might be a mediator of pro-fibrotic
Wnt signaling in Dupuytren’s disease.
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